Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing
an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred …

Glioblastoma (GBM) is the most common and aggressive central nervous system tumor,
requiring multimodal management. Due to its malignant behavior and infiltrative growth …

Chimeric antigen receptor (CAR) T-cell immunotherapy refers to an adoptive
immunotherapy that has rapidly developed in recent years. It is a novel type of treatment that …

Chimeric antigen receptor (CAR)-T cell therapy has become one of the hot topics in tumor
immunity research in recent years. Although CAR-T cell therapy is highly effective in treating …

Cancer research has become increasingly complex over the past few decades as
knowledge of the heterogeneity of cancer cells, their proliferative ability, and their tumor …

Glioblastoma (GBM) is the most common malignant primary brain cancer in adults. It is
always resistant to existing treatments, including surgical resection, postoperative …

Despite advancements in standard treatments, the prognosis of Glioblastoma (GBM)
remains poor, prompting research for novel therapies. Immunotherapy is a promising …

Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy
strategy and has achieved satisfactory outcomes in the treatment of hematological …

Glioblastoma multiforme (GBM) is one of the deadliest brain tumors with an unfavorable
prognosis and overall survival of approximately 20 months following diagnosis. The current …